50% | 6s | $910bn | 1 in 5 |
of all child deaths under age 5 are due to poor nutrition (1) | every 6 seconds, a person dies from diabetes (2) | actual costs of Diabetes-related complications (3) | urban children in India are pre-diabetic(4) |
Sources: (1) Bill and Melinda Gates Foundation; (2) World Health Organization Global Health Expenditure Database, 2014; (3) IDF Diabetes Atlas, 6th ed. Brussels, International Diabetes Federation, 2013; (4) WEF and Harvard School of Public Health “Global Economic Burden of Non-communicable diseases”; |
FriendsLearn has achieved pioneering milestones in collaboration with scientists at Carnegie Mellon University, Johns Hopkins Bloomberg School of Public Health, Stanford School of Medicine, University of Michigan, Pittsburgh Children’s Hospital UPMC, Kansas Medical Center, Baylor College of Medicine and the National University of Singapore.
US Patent # 7,770,114 |
US Patent Pending: 16/653,937 |
System and Method of Using |
Systems and Methods for Digital Vaccine |
Fooya is a non-invasive, low-risk and clinically-proven digital vaccine technology delivered through a commercially available, subscription driven, game-like, mobile App, for children to download on iOS / Android / PCs. Based on published results from 4 pilot, cross-sectional clinical trials conducted with over 1000 children, researchers found that children who use FOOYA! make healthier food choices in the real world.
View Video100s of schools have applied to gain access to our School Health program and to partner with the Digital Vaccine Project at Carnegie Mellon University. Select schools that have demonstrated track record of Health Programming will be considered after a rigrious evaluation and eligibility matching process. Click here to Apply
FriendsLearn is a Bio and Health Tech company that has defined a new class of disease prevention through technology, known as Digital Vaccines, in partnership with world-renowned academic scientists and researchers. FriendsLearn is a founding research translation and technology commercialization partner of the Digital Vaccine Project at Carnegie Mellon University.
With offices in San Francisco, California and Chennai, India, FriendsLearn has achieved pioneering milestones in collaboration with scientists at Carnegie Mellon University, Johns Hopkins Bloomberg School of Public Health, Stanford School of Medicine, University of Michigan, Pittsburgh Children’s Hospital UPMC, Kansas Medical Center, Baylor College of Medicine and the National University of Singapore.
Digital Vaccines are a subcategory of the field of Digital Therapeutics. The company's Digital Vaccine pipeline of candidates are derivatives of a proprietary Machine Learning and Deep Learning enabled Neuromodulation and Neurocognitive Training platform. These technologies are clinically validated non-invasive game-like mobile Virtual Reality Apps. FriendsLearn has a commercially deployed candidate, delivered as the mobile App for children on iOS and Android devices - FOOYA! - based on 10 years of published R&D in the prevention of lifestyle diseases. The company has expanded the platform to disease management, as well as towards prevention of infectious diseases.
NASSCOM featured FriendsLearn’s Digital Vaccines as a "2020 Digital Disruptor" and as an example of Deep Tech innovation during the 2020 NASSCOM Technology Leadership Forum in Mumbai. Carnegie Mellon University featured Digital Vaccines as one of the top breakthrough in technology in their "Year in review" as well as described the underlying scientific advances as a "new frontier in disease prevention technology".
To learn more, email [email protected]